Premium
PVU II POLYMORPHISM OF LST‐1 (LEUCOCYTE SPECIFIC TRANSCRIPT‐1) IN TYPE I DIABETES MELLITUS, GRAVES’ DISEASE AND HEALTHY CONTROLS
Author(s) -
Rau H.,
Usadel K.H.,
Ommert S.,
Badenhoop K.
Publication year - 1995
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.1995.tb00242.x
Subject(s) - allele , biology , restriction fragment length polymorphism , polymorphism (computer science) , medicine , disease , diabetes mellitus , endocrinology , autoimmune disease , gene , immunopathology , genotype , genetics , immunology
SUMMARY The polymorphism of the LST‐1 gene (the human homologue of the mouse B144 gene) can be identified by Pvu II restriction enzyme digestion. We investigated the contribution of this RFLP to disease susceptibility in 117 patients with type I diabetes mellitus (IDDM), 110 with Graves’ disease (GD) and 93 healthy controls. The distribution of the different LST‐1 alleles (LST‐1*1:1323bp, LST‐1*2:610bp/713) was similar among IDDM and GD patients as well as in controls. The combination of DQA1*0501, DQB1*0201 and DQB1*0301, all predisposing to endocrine autoimmune disease, with LST‐1*1 or LST‐1*2 was not increased in patients. Analysis of two informative families with IDDM demonstrated cosegregation of DQA1 and DQB1 alleles with LST‐1 alleles. No association of LST‐1 polymorphisms with IDDM nor GD could be demonstrated.